Welcome : Guest

TG Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about TG Therapeutics, Inc., which is principally involved in Biopharmaceuticals Business. Illustrated with 19 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-65532
Price: $950
Company Type: Public
Pages: 21
Date: November 2016
Market Data Tables: 19

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Multiple Sclerosis......3
Table 1: Multiple Sclerosis Disease Occurrence by Type Worldwide (2015) - Percentage Breakdown by Volume for Begin MS, Primary Progressive MS, Relapsing-Remiting MS, and Secondary Progressive MS......3
Table 2: Multiple Sclerosis Patient Care Expenditure by Category Worldwide (2015) - Percentage Breakdown by Value for Adaptations, Ambulatory Care, Disease Modifying Drugs, Early Retirement, Hospital Inpatient Care, Informal Care, Prescription and OTC Drugs, Services, Sick-leave and Redused Working Time, and Tests......4
Table 3: Relapsing-Remitting Multiple Sclerosis (RRMS) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union (EU), US, Rest of World (RoW)......5
Table 4: No. of Tcelna (Imilecleucel-T) Secondary Progressive Multiple Sclerosis Patients by Category in the US (2015) - Percentage Breakdown for Primary Progressive MS Patients, Relapsing-Remitting MS Patients, and Secondary-Progressive MS Patients......6
Multiple Sclerosis......7
Table 5: Market Shares of Leading Multiple Sclerosis Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Biogen Idec, Novartis AG, Sanofi S.A., and Others......7
Table 6: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by No. of Patients for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......8
Table 7: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by Value for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......9
Cancer......10
Table 8: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......10
Table 9: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......11
Table 10: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin's Lymphoma (NHL)......12
Rheumatoid Arthritis......13
Table 11: Rheumatoid Arthritis Market by Product Type Worldwide (2015) - Percentage Share Breakdown by Value Sales for ENBREL, HUMIRA, REMICADE, and Others......13
Chronic Lymphocytic Leukemia (CLL)......14
Table 12: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......14
Table 13: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......15
Table 14: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......16
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......17
Table 15: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......17
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......18
Table 16: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......18
Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL)......19
Table 17: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Other......19
Table 18: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Aggressive Non-Hodgkin Lymphoma (aNHL) in the US (2015) - Percentage Breakdown by Value for ABT-199, Ibrutinib, Idelalisib, and Others......20
Systemic Lupus Erythematosus with Benlysta......21
Table 19: Systemic Lupus Erythematosus with Benlysta Market by Category in the US (2015) - Percentage Share Breakdown by Value for Mild Systemic Lupus Erythematosus (excluded in target population), Moderate Systemic Lupus Erythematosus, and Severe Systemic Lupus Erythematosus......21